Adipose Tissue Insulin Resistance Up in Obese-NGT, IGT, T2DM

Share this content:
Adipose Tissue Insulin Resistance Up in Obese-NGT, IGT, T2DM
Adipose Tissue Insulin Resistance Up in Obese-NGT, IGT, T2DM

MONDAY, Jan. 9, 2017 (HealthDay News) -- Resistance to the antilipolytic effect of insulin (Adipo-IR) is increased in obese individuals with normal glucose tolerance (NGT), and in those with impaired glucose tolerance (IGT) and type 2 diabetes (T2DM), according to a study published online Jan. 4 in Diabetes.

Amalia Gastaldelli, Ph.D., from the University of Texas Health Science Center at San Antonio, and colleagues examined the role of Adipo-IR in a large group of NGT, IGT, and T2DM subjects. The authors evaluated Adipo-IR, peripheral IR, and β-cell function in 302 subjects with varying glucose tolerance.

The researchers found that, compared with lean-NGT, fasting Adipo-IR was increased two-fold in obese-NGT and IGT and three-fold in T2DM (4.1 ± 0.3 versus 8.0 ± 1.1, 9.2 ± 0.7, and 11.9 ± 0.6, respectively). Progressive decline in β-cell function correlated with a progressive impairment in free fatty acid (FFA) suppression during the oral glucose tolerance test; when subjects became overtly diabetic the increase in mean plasma glucose concentration became manifest.

"In conclusion, the progressive decline in β-cell function that begins in 'normal' glucose tolerant individuals is associated with a progressive increase in FFA and fasting Adipo-IR," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Single-Payer Health System Bill Moves Forward in California

Single-Payer Health System Bill Moves Forward in California

Not yet clear where money for the single-payer system would come from

Regorafenib Approved for Hepatocellular Carcinoma

Regorafenib Approved for Hepatocellular Carcinoma

It is the first approved treatment for HCC in almost a decade

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Rates of worsening low in patients receiving aflibercept, bevacizumab, or ranibizumab

is free, fast, and customized just for you!

Already a member?

Sign In Now »